Confederation / Finances / Subsidies / A231.0431
Subsidy · 316 / BAG · FDHA
Covid: Beiträge an Herstellung/Entwicklung von Arzneimitteln
- Credit number
- A231.0431
- 2025
- 0.0 m CHF
- Recipient according to the EFV
- Unternehmen
- Legal basis
- Covid-19-Gesetz (SR 818.102), Art. 3, Abs. 2, Bst. e (in Kraft bis 30.6.2024).
- Form
- A-fonds-perdu-Beitrag · Financial aid 100 %, compensation 0 %
- Subsidised since
- 2021
- Service
- Entwicklung neuartiger Therapien gegen Covid-19
- Task area
- Health
Amount 1980–2025, m CHF
In Parliament
The votes whose subject names this credit number: the budget and its supplements. What yes and no meant stands as the Parliamentary Services publish it.
No vote on this credit has been recorded.
Interest ties
Declarations in the register of interests are visible to signed-in users only. Sign in →
A tie shows what a member declares in the official register, and rests on evidence the editors hold. It says nothing about the reasons for a vote.
All values as a table
| Year | m CHF |
|---|---|
| 1980 | 0.0 |
| 1981 | – |
| 1982 | – |
| 1983 | – |
| 1984 | – |
| 1985 | 0.0 |
| 1986 | – |
| 1987 | – |
| 1988 | – |
| 1989 | – |
| 1990 | 0.0 |
| 1991 | – |
| 1992 | – |
| 1993 | – |
| 1994 | – |
| 1995 | 0.0 |
| 1996 | – |
| 1997 | – |
| 1998 | – |
| 1999 | – |
| 2000 | 0.0 |
| 2001 | – |
| 2002 | – |
| 2003 | – |
| 2004 | – |
| 2005 | 0.0 |
| 2006 | 0.0 |
| 2007 | 0.0 |
| 2008 | 0.0 |
| 2009 | 0.0 |
| 2010 | 0.0 |
| 2011 | 0.0 |
| 2012 | 0.0 |
| 2013 | 0.0 |
| 2014 | 0.0 |
| 2015 | 0.0 |
| 2016 | 0.0 |
| 2017 | 0.0 |
| 2018 | 0.0 |
| 2019 | 0.0 |
| 2020 | 0.0 |
| 2021 | 11.8 |
| 2022 | 2.3 |
| 2023 | 0.2 |
| 2024 | 1.9 |
| 2025 | 0.0 |
Everything the subsidy database says
The Federal Finance Administration’s wording, unaltered and in German.
- Anteil Abgeltung in %
- 0
- Anteil Finanzhilfe in %
- 100
- Archiviert ab
- 2025
- Aufgabengebiet
- Gesundheit
- Departement
- EDI
- Form der Subvention
- A-fonds-perdu-Beitrag
- Kreditnummer
- A231.0431
- Pflichtbeitrag an internationale Organisationen in %
- 0
- Rechtsgrundlage
- Covid-19-Gesetz (SR 818.102), Art. 3, Abs. 2, Bst. e (in Kraft bis 30.6.2024).
- Subventionierte Leistungen
- Entwicklung neuartiger Therapien gegen Covid-19
- Subventionierung der Leistung seit
- 2021
- Subventionsbezeichnung
- Covid: Beiträge an Herstellung/Entwicklung von Arzneimitteln
- Subventionsempfänger
- Unternehmen
- Verwaltungseinheit Nr.
- 316 / BAG
- Übergeordnete Ziele des Bundes
- Gewährleistung des Zugangs zu medizinischen Leistungen in Zusammenhang mit Covid-19, die nicht über die OKP finanziert werden.
Source: Eidgenössische Finanzverwaltung EFV, retrieved 14.09.2026. Raw data
Not an official publication. The figures stand as the Federal Finance Administration publishes them; schwur.ch only rounds them.